nach oben

Journal of Clinical Immunology

Erschienen in:

01.10.2015 | CME Review

The Ying and Yang of STAT3 in Human Disease

verfasst von: Tiphanie P. Vogel, Joshua D. Milner, Megan A. Cooper

Erschienen in: Journal of Clinical Immunology | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

The transcription factor signal transducer and activator of transcription 3 (STAT3) is a critical regulator of multiple, diverse cellular processes. Heterozgyous, germline, loss-of-function mutations in STAT3 lead to the primary immune deficiency Hyper-IgE syndrome. Heterozygous, somatic, gain-of-function mutations in STAT3 have been reported in malignancy. Recently, germline, heterozygous mutations in STAT3 that confer a gain-of-function have been discovered and result in early-onset, multi-organ autoimmunity. This review summarizes what is known about the role of STAT3 in human disease.

Zhong Z, Wen Z, Darnell Jr JE. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994;264(5155):95–8.PubMedCrossRef

Levy DE, Darnell Jr JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651–62.PubMedCrossRef

Holland SM et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007;357(16):1608–19.PubMedCrossRef

Minegishi Y et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448(7157):1058–62.PubMedCrossRef

Koskela HL et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905–13.PubMedCentralPubMedCrossRef

Flanagan SE et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet. 2014;46(8):812–4.PubMedCentralPubMedCrossRef

Milner JD et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015;125(4):591–9.PubMedCrossRef

Haapaniemi EM et al. Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. Blood. 2015;125(4):639–48.PubMedCentralPubMedCrossRef

O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161–70.PubMedCrossRef

10.

Mogensen TH. STAT3 and the Hyper-IgE syndrome: clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties. JAKSTAT. 2013;2(2), e23435.PubMedCentralPubMed

11.

UniProt C. UniProt: a hub for protein information. Nucleic Acids Res. 2015;43(Database issue):D204–12.

12.

Ng IH et al. Selective STAT3-alpha or -beta expression reveals spliceform-specific phosphorylation kinetics, nuclear retention and distinct gene expression outcomes. Biochem J. 2012;447(1):125–36.PubMedCentralPubMedCrossRef

13.

Shao H, Quintero AJ, Tweardy DJ. Identification and characterization of cis elements in the STAT3 gene regulating STAT3 alpha and STAT3 beta messenger RNA splicing. Blood. 2001;98(13):3853–6.PubMedCrossRef

14.

Dewilde S et al. Of alphas and betas: distinct and overlapping functions of STAT3 isoforms. Front Biosci. 2008;13:6501–14.PubMedCrossRef

15.

Maritano D et al. The STAT3 isoforms alpha and beta have unique and specific functions. Nat Immunol. 2004;5(4):401–9.PubMedCrossRef

16.

Chakraborty A, Tweardy DJ. Granulocyte colony-stimulating factor activates a 72-kDa isoform of STAT3 in human neutrophils. J Leukoc Biol. 1998;64(5):675–80.PubMed

17.

Hevehan DL, Miller WM, Papoutsakis ET. Differential expression and phosphorylation of distinct STAT3 proteins during granulocytic differentiation. Blood. 2002;99(5):1627–37.PubMedCrossRef

18.

Villarino AV et al. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol. 2015;194(1):21–7.PubMedCrossRef

19.

Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity. 2012;36(4):515–28.PubMedCentralPubMedCrossRef

20.

Wake, M.S. and C.J. Watson. STAT3 the oncogene - still eluding therapy? FEBS J. 2015;282(14):2600–11.

21.

Yang J, Stark GR. Roles of unphosphorylated STATs in signaling. Cell Res. 2008;18(4):443–51.PubMedCrossRef

22.

Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene. 2000;19(21):2628–37.PubMedCrossRef

23.

Carow B, Rottenberg ME. SOCS3, a major regulator of infection and inflammation. Front Immunol. 2014;5:58.PubMedCentralPubMedCrossRef

24.

Wegrzyn J et al. Function of mitochondrial Stat3 in cellular respiration. Science. 2009;323(5915):793–7.PubMedCentralPubMedCrossRef

25.

Camporeale A, Poli V. IL-6, IL-17 and STAT3: a holy trinity in auto-immunity? Front Biosci (Landmark Ed). 2012;17:2306–26.CrossRef

26.

Takeda K et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A. 1997;94(8):3801–4.PubMedCentralPubMedCrossRef

27.

Tangye SG, Cook MC, Fulcher DA. Insights into the role of STAT3 in human lymphocyte differentiation as revealed by the hyper-IgE syndrome. J Immunol. 2009;182(1):21–8.PubMedCrossRef

28.

Kane A et al. STAT3 is a central regulator of lymphocyte differentiation and function. Curr Opin Immunol. 2014;28:49–57.PubMedCrossRef

29.

Fornek JL et al. Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells. Blood. 2006;107(3):1085–91.PubMedCentralPubMedCrossRef

30.

Cui W et al. An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells. Immunity. 2011;35(5):792–805.PubMedCentralPubMedCrossRef

31.

Takeda K et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity. 1999;10(1):39–49.PubMedCrossRef

32.

Gotthardt D et al. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood. 2014;124(15):2370–9.PubMedCrossRef

33.

Davis SD, Schaller J, Wedgwood RJ. Job’s Syndrome. Recurrent, “cold”, staphylococcal abscesses. Lancet. 1966;1(7445):1013–5.PubMedCrossRef

34.

Buckley RH, Wray BB, Belmaker EZ. Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics. 1972;49(1):59–70.PubMed

35.

Grimbacher B et al. Hyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorder. N Engl J Med. 1999;340(9):692–702.PubMedCrossRef

36.

Chandesris MO et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore). 2012;91(4):e1–19.PubMedCentralCrossRef

37.

Jiao H et al. Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups. Mol Immunol. 2008;46(1):202–6.PubMedCrossRef

38.

Schimke LF et al. Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. J Allergy Clin Immunol. 2010;126(3):611–7.PubMedCrossRef

39.

Woellner C et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol. 2010;125(2):424–32.PubMedCentralPubMedCrossRef

40.

Siegel AM et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity. 2011;35(5):806–18.PubMedCentralPubMedCrossRef

41.

Chandesris MO et al. Frequent and widespread vascular abnormalities in human signal transducer and activator of transcription 3 deficiency. Circ Cardiovasc Genet. 2012;5(1):25–34.PubMedCrossRef

42.

Wallet N et al. Diffuse large B-cell lymphoma in hyperimmunoglobulinemia E syndrome. Clin Lymphoma Myeloma. 2007;7(6):425–7.PubMedCrossRef

43.

Sowerwine KJ, Holland SM, Freeman AF. Hyper-IgE syndrome update. Ann N Y Acad Sci. 2012;1250:25–32.PubMedCentralPubMedCrossRef

44.

Siegel AM et al. Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation. J Allergy Clin Immunol. 2013;132(6):1388–96.PubMedCrossRef

45.

Wolach O et al. Variable clinical expressivity of STAT3 mutation in hyperimmunoglobulin E syndrome: genetic and clinical studies of six patients. J Clin Immunol. 2014;34(2):163–70.PubMedCrossRef

46.

Grimbacher B et al. Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet. 1999;65(3):735–44.PubMedCentralPubMedCrossRef

47.

Milner JD et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008;452(7188):773–6.PubMedCentralPubMedCrossRef

48.

Ma CS et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008;205(7):1551–7.PubMedCentralPubMedCrossRef

49.

de Beaucoudrey L et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med. 2008;205(7):1543–50.PubMedCentralPubMedCrossRef

50.

Burkett PR, Meyer Zu Horste G, Kuchroo VK. Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity. J Clin Invest. 2015;125(6):2211–9.PubMedCrossRef

51.

Hsu AP et al. Intermediate phenotypes in patients with autosomal dominant hyper-IgE syndrome caused by somatic mosaicism. J Allergy Clin Immunol. 2013;131(6):1586–93.PubMedCentralPubMedCrossRef

52.

Avery DT et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med. 2010;207(1):155–71.PubMedCentralPubMedCrossRef

53.

Meyer-Bahlburg A et al. Heterozygous signal transducer and activator of transcription 3 mutations in hyper-IgE syndrome result in altered B-cell maturation. J Allergy Clin Immunol. 2012;129(2):559–62.PubMedCrossRef

54.

Deenick EK et al. Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells. J Exp Med. 2013;210(12):2739–53.PubMedCentralPubMedCrossRef

55.

Ma CS et al. Functional STAT3 deficiency compromises the generation of human T follicular helper cells. Blood. 2012;119(17):3997–4008.PubMedCentralPubMedCrossRef

56.

Ives ML et al. Signal transducer and activator of transcription 3 (STAT3) mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8(+) T-cell memory formation and function. J Allergy Clin Immunol. 2013;132(2):400–11.PubMedCentralPubMedCrossRef

57.

Wilson RP et al. STAT3 is a critical cell-intrinsic regulator of human unconventional T cell numbers and function. J Exp Med. 2015;212(6):855–64.PubMedCrossRef

58.

Saito M et al. Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. J Exp Med. 2011;208(2):235–49.PubMedCentralPubMedCrossRef

59.

Steward-Tharp SM et al. A mouse model of HIES reveals pro- and anti-inflammatory functions of STAT3. Blood. 2014;123(19):2978–87.PubMedCentralPubMedCrossRef

60.

Zhang LY et al. Clinical features, STAT3 gene mutations and Th17 cell analysis in nine children with hyper-IgE syndrome in mainland China. Scand J Immunol. 2013;78(3):258–65.PubMedCrossRef

61.

Sundin M et al. Novel STAT3 mutation causing hyper-IgE syndrome: studies of the clinical course and immunopathology. J Clin Immunol. 2014;34(4):469–77.PubMedCrossRef

62.

Mogensen TH, Jakobsen MA, Larsen CS. Identification of a novel STAT3 mutation in a patient with hyper-IgE syndrome. Scand J Infect Dis. 2013;45(3):235–8.PubMedCrossRef

63.

Saikia B et al. Hyper-IgE syndrome with a novel STAT3 mutation-a single center study from India. Asian Pac J Allergy Immunol. 2014;32(4):321–7.PubMed

64.

Renner ED et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol. 2008;122(1):181–7.PubMedCentralPubMedCrossRef

65.

Yong PF et al. An update on the hyper-IgE syndromes. Arthritis Res Ther. 2012;14(6):228.PubMedCentralPubMedCrossRef

66.

Goussetis E et al. Successful long-term immunologic reconstitution by allogeneic hematopoietic stem cell transplantation cures patients with autosomal dominant hyper-IgE syndrome. J Allergy Clin Immunol. 2010;126(2):392–4.PubMedCrossRef

67.

Nester TA et al. Effects of allogeneic peripheral stem cell transplantation in a patient with job syndrome of hyperimmunoglobulinemia E and recurrent infections. Am J Med. 1998;105(2):162–4.PubMedCrossRef

68.

Gennery AR et al. Bone marrow transplantation does not correct the hyper IgE syndrome. Bone Marrow Transplant. 2000;25(12):1303–5.PubMedCrossRef

69.

Patel NC et al. Successful haploidentical donor hematopoietic stem cell transplant and restoration of STAT3 function in an adolescent with autosomal dominant Hyper-IgE syndrome. J Clin Immunol. 2015;35(5):479–85.PubMedCrossRef

70.

Jerez A et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048–57.PubMedCentralPubMedCrossRef

71.

Rajala HL et al. Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. Ann Med. 2014;46(3):114–22.PubMedCrossRef

72.

Pilati C et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med. 2011;208(7):1359–66.PubMedCentralPubMedCrossRef

73.

Jerez A et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013;122(14):2453–9.PubMedCentralPubMedCrossRef

74.

Verbsky JW, Chatila TA. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases. Curr Opin Pediatr. 2013;25(6):708–14.PubMedCentralPubMedCrossRef

75.

Oliveira JB, Fleisher T. Autoimmune lymphoproliferative syndrome. Curr Opin Allergy Clin Immunol. 2004;4(6):497–503.PubMedCrossRef

76.

Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830–5.PubMedCrossRef

77.

Chaudhry A et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science. 2009;326(5955):986–91.PubMedCentralPubMedCrossRef

78.

Cohen AC et al. Cutting edge: decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency. J Immunol. 2006;177(5):2770–4.PubMedCrossRef

79.

Komatsu N et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med. 2014;20(1):62–8.PubMedCrossRef

80.

Gagliani N et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature. 2015;523(7559):221–5.

81.

Tsoi LC et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44(12):1341–8.PubMedCentralPubMedCrossRef

82.

Danoy P et al. Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn’s disease. PLoS Genet. 2010;6(12), e1001195.PubMedCentralPubMedCrossRef

83.

Seddighzadeh M et al. Variants within STAT genes reveal association with anticitrullinated protein antibody-negative rheumatoid arthritis in 2 European populations. J Rheumatol. 2012;39(8):1509–16.PubMedCrossRef

84.

Barrett JC et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40(8):955–62.PubMedCentralPubMedCrossRef

85.

Frampton JE. Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis. Paediatr Drugs. 2013;15(6):515–31.PubMedCrossRef

86.

van Vollenhoven RF et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–19.PubMedCrossRef

87.

Lee EB et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377–86.PubMedCrossRef

88.

Dupuis S et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science. 2001;293(5528):300–3.PubMedCrossRef

89.

Dupuis S et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet. 2003;33(3):388–91.PubMedCrossRef

90.

Averbuch D et al. The clinical spectrum of patients with deficiency of signal transducer and activator of transcription-1. Pediatr Infect Dis J. 2011;30(4):352–5.PubMedCrossRef

91.

van de Veerdonk FL et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med. 2011;365(1):54–61.PubMedCrossRef

92.

Liu L et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med. 2011;208(8):1635–48.PubMedCentralPubMedCrossRef

93.

Hambleton S et al. STAT2 deficiency and susceptibility to viral illness in humans. Proc Natl Acad Sci U S A. 2013;110(8):3053–8.PubMedCentralPubMedCrossRef

94.

Kofoed EM et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med. 2003;349(12):1139–47.PubMedCrossRef

95.

Yildiz M et al. Activating STAT6 mutations in follicular lymphoma. Blood. 2015;125(4):668–79.PubMedCrossRef

96.

McDonald DR. TH17 deficiency in human disease. J Allergy Clin Immunol. 2012;129(6):1429–35.PubMedCentralPubMedCrossRef

97.

He J et al. STAT3 mutations correlated with hyper-IgE syndrome lead to blockage of IL-6/STAT3 signalling pathway. J Biosci. 2012;37(2):243–57.PubMedCrossRef

98.

Uzel G et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol. 2013;131(6):1611–23.PubMedCentralPubMedCrossRef

99.

Kristensen T et al. Clinical relevance of sensitive and quantitative STAT3 mutation analysis using next-generation sequencing in T-cell large granular lymphocytic leukemia. J Mol Diagn. 2014;16(4):382–92.PubMedCrossRef

100.

Ohgami RS et al. STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia. Leukemia. 2013;27(11):2244–7.PubMedCrossRef

101.

Miyazaki K et al. An adolescent with marked hyperimmuno-globulinemia E showing minimal change nephrotic syndrome and a STAT3 gene mutation. Clin Nephrol. 2011;75(4):369–73.PubMedCrossRef

102.

Giacomelli M et al. SH2-domain mutations in STAT3 in hyper-IgE syndrome patients result in impairment of IL-10 function. Eur J Immunol. 2011;41(10):3075–84.PubMedCrossRef

103.

Al Khatib S et al. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome. J Allergy Clin Immunol. 2009;124(2):342–8.PubMedCentralPubMedCrossRef

Titel: The Ying and Yang of STAT3 in Human Disease
verfasst von: Tiphanie P. Vogel
Joshua D. Milner
Megan A. Cooper
Publikationsdatum: 01.10.2015
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 7/2015
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-015-0187-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2015

Astute Clinician Report: A Novel 10 bp Frameshift Deletion in Exon 2 of ICOS Causes a Combined Immunodeficiency Associated with an Enteritis and Hepatitis

Primary Immunodeficiency Diseases in Saudi Arabia: a Tertiary Care Hospital Experience over a Period of Three Years (2010–2013)

Use of Polyclonal Intravenous Immunoglobulin at a Paediatric Referral Hospital in South Africa Between 2009 and 2012

Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in a Patient with Chronic Granulomatous Disease and Active Infection: A First Report

Cerebral Vasculitis in X-linked Lymphoproliferative Disease Cured by Matched Unrelated Cord Blood Transplant